These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 15865829

  • 1. The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease.
    Tulloh RM, Feltes TF.
    Cardiol Young; 2005 Jun; 15(3):274-8. PubMed ID: 15865829
    [Abstract] [Full Text] [Related]

  • 2. Infection by the respiratory syncytial virus in infants and young children at high risk.
    Bonnet D, Schmaltz AA, Feltes TF.
    Cardiol Young; 2005 Jun; 15(3):256-65. PubMed ID: 15865827
    [Abstract] [Full Text] [Related]

  • 3. Recommendations for the use of palivizumab as prophylaxis against respiratory syncytial virus in infants with congenital cardiac disease.
    Tulloh R, Marsh M, Blackburn M, Casey F, Lenney W, Weller P, Keeton BR, Working Group of the British Paediatric Cardiac Association.
    Cardiol Young; 2003 Oct; 13(5):420-3. PubMed ID: 14694935
    [Abstract] [Full Text] [Related]

  • 4. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Acute and long-term effects of infection by the respiratory syncytial virus in children with congenital cardiac malformations.
    Feltes TF, Groothuis JR.
    Cardiol Young; 2005 Jun; 15(3):266-73. PubMed ID: 15865828
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Palivizumab in the prophylaxis of respiratory syncytial virus infection.
    Cardenas S, Auais A, Piedimonte G.
    Expert Rev Anti Infect Ther; 2005 Oct; 3(5):719-26. PubMed ID: 16207163
    [Abstract] [Full Text] [Related]

  • 9. [Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)].
    Pin I, Pilenko C, Bost M.
    Allerg Immunol (Paris); 2002 Dec; 34(10):371-4. PubMed ID: 12575622
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC.
    N Engl J Med; 1993 Nov 18; 329(21):1524-30. PubMed ID: 8413475
    [Abstract] [Full Text] [Related]

  • 14. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A, Langley JM, Thomas W, Scott J.
    Can J Cardiol; 2007 May 01; 23(6):463-6. PubMed ID: 17487291
    [Abstract] [Full Text] [Related]

  • 15. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I, Tough S, Gillis L, Majaesic C.
    Pediatr Pulmonol; 2006 Dec 01; 41(12):1167-74. PubMed ID: 17058279
    [Abstract] [Full Text] [Related]

  • 16. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
    Giebels K, Marcotte JE, Podoba J, Rousseau C, Denis MH, Fauvel V, Laberge S.
    Pediatr Pulmonol; 2008 Feb 01; 43(2):169-74. PubMed ID: 18085710
    [Abstract] [Full Text] [Related]

  • 17. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease--who should receive it?
    Sunnegårdh J.
    Acta Paediatr; 2006 Apr 01; 95(4):388-90. PubMed ID: 16720482
    [Abstract] [Full Text] [Related]

  • 18. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
    Prescrire Int; 2004 Dec 01; 13(74):213-6. PubMed ID: 15612142
    [Abstract] [Full Text] [Related]

  • 19. Economic evaluation of palivizumab in children with congenital heart disease: a Canadian perspective.
    Harris KC, Anis AH, Crosby MC, Cender LM, Potts JE, Human DG.
    Can J Cardiol; 2011 Dec 01; 27(4):523.e11-5. PubMed ID: 21664100
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
    Elhassan NO, Sorbero ME, Hall CB, Stevens TP, Dick AW.
    Arch Pediatr Adolesc Med; 2006 Oct 01; 160(10):1070-6. PubMed ID: 17018467
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.